Skip to main content
Genome-Informed Targeted Therapy for Osteosarcoma.
The genetics of splicing in neuroblastoma.
Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
FGFR fusions in the driver's seat.
G34, another connection between MYCN and a pediatric tumor.
Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer.
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.